The findings of the new Phase 3 trial, which involved more than 32,000 participants, could boost confidence in the vaccine, which was originally developed by Oxford University.
The trial showed the vaccine was well tolerated and there were no safety concerns, the company said. According to AstraZeneca, an independent committee found that “21,583 participants who received at least one dose of the vaccine did not have an increased risk of thrombosis or events characterized by thrombosis.”
The new data comes from Phase 3 clinical trials conducted in the U.S., Chile and Peru. AstraZeneca says it plans to submit the findings to a scientific journal for peer review.
For its part, Press Xford said the findings add to previous trial data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom, the university said in a press release.
As part of the trial, more than 32,000 volunteers recruited at all ages received either two doses of the vaccine or a placebo vaccine at four-week intervals.
An emergency investigation by the European Medicines Agency (EMA) last Thursday concluded that the vaccine was “safe and effective” in preventing coronavirus and was not “associated with an increased risk of thromboembolic events or overall blood clots.”
Sarah Gilbert, co-designer of the vaccine and professor of vaccine at Oxford University, praised the data for providing “further confirmation of the safety and effectiveness” of the vaccine.
Andrew Pollard, a lead investigator for the vaccine at the University of Oxford, said the AstraZeneca data were “consistent with the results of tests conducted under the auspices of Oxford”, adding that they are “against all ages.” Extensive use of the vaccine for people of all diverse backgrounds. “
.
